Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

被引：5
|
作者：
Beltran, Himisha
Dowlati, Afshin
Jain, Prantesh
Johnson, Melissa Lynne
Sanborn, Rachel E.
Thompson, Jonathan Robert
Mamdani, Hirva
Schenk, Erin L.
Aggarwal, Rahul Raj
Sankar, Kamya
Gramza, Ann W.
Anand, Banmeet S.
Choudhury, Noura J.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Case Western Reserve Univ, Univ Hosp Siedman Canc Ctr, Cleveland, OH USA
[3] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Earle A Chiles Res Inst, Portland, OR USA
[6] Froedtert, Milwaukee, WI USA
[7] Med Coll Wisconsin, Workforce Hlth, Milwaukee, WI USA
[8] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[9] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[10] Univ Calif San Francisco, San Francisco, CA USA
[11] Cedars Sinai Med Ctr, Los Angeles, CA USA
[12] Harpoon Therapeut Inc, South San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-492-199-2823-7422-11198; 283-197-6219; 613-225-2577-2545; 283-183-138-226; 261-492-199-2823; 613-615-646-4685-2424; 613-225-2782; 6; 4; 3; 38092-34755; 38092-21757; 38092-21759; 5; 2; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：121 / 121
页数：1
相关论文
共 36 条
  • [1] Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Choudhury, N.
    Jain, P.
    Dowlati, A.
    Thompson, J.
    Johnson, M. L.
    Mamdani, H.
    Sanborn, R. E.
    Schenk, E. L.
    Aggarwal, R.
    Sankar, K.
    Walker, L. N.
    Anand, B.
    Beltran, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S486 - S486
  • [2] Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)
    Beltran, Himisha
    Johnson, Melissa Lynne
    Jain, Prantesh
    Schenk, Erin L.
    Sanborn, Rachel E.
    Thompson, Jonathan Robert
    Dowlati, Afshin
    Mamdani, Hirva
    Aggarwal, Rahul Raj
    Anand, Banmeet S.
    Gramza, Ann W.
    Choudhury, Noura J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.
    Johnson, Melissa Lynne
    Dy, Grace K.
    Mamdani, Hirva
    Dowlati, Afshin
    Schoenfeld, Adam Jacob
    Pacheco, Jose Maria
    Sanborn, Rachel E.
    Menon, Smitha Patiyil
    Santiago, Linda
    Yaron, Yifah
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Anti-tumor activity of HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, is enhanced by combining with an anti-PD-L1 antibody in an immunocompetent mouse model
    Valenzuela, Laura B.
    Wu, Chi-Heng
    Aaron, Wade
    Banzon, Raphalea R.
    Bush, Mabel
    Lin, S. Jack
    Rocha, Sony S.
    Thothathri, Subramanian
    Wesche, Holger
    Molloy, Mary Ellen
    Anand, Banmeet S.
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Long-term anti-tumor immunity induced by of HPN328, a DLL3-targeting trispecific, half-life extended T cell engager, in a preclinical immunocompetent mouse model
    Molloy, Mary Ellen
    Valenzuela, Laura B.
    Wu, Chi-Heng
    Wesche, Holger
    Anand, Banmeet S.
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Fong, Lawrence
    Beer, Tomasz M.
    Gao, Xin
    Geynisman, Daniel M.
    Burris, Howard A., III
    Strauss, James Fredric
    Courtney, Kevin Dale
    Quinn, David I.
    VanderWeele, David James
    Yaron, Yifah
    Law, Che-Leung
    Stein, Mark N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Rottey, Sylvie
    Aparicio, Ana
    Greil, Richard
    Reimers, Melissa Andrea
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [8] Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Aparicio, Ana
    Heidenreich, Axel
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Shetty, Aditya
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bendell, Johanna C.
    Fong, Lawrence
    Stein, Mark N.
    Beer, Tomasz M.
    Ross, Ashley
    Gao, Xin
    Weitzman, Aaron
    Austin, Richard
    Ganti, Vaishnavi
    Law, Che-Leung
    Lemon, Bryan
    Wesche, Holger
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas
    Gambardella, Valentina
    Greystoke, Alastair
    Reck, Martin
    Liu, Meiruo
    Mueller, Martha
    Duenzinger, Ulrich
    Bergsland, Emily B.
    Owonikoko, Taofeek
    CANCER RESEARCH, 2024, 84 (07)
1234